Tolero Pharmaceuticals   Report issue

For profit Phase 1 Phase 2
Founded: Lehi UT United States (2011)
Status: Acquired by Sumitomo Dainippon (2017)

Organization Overview

First Clinical Trial
2016
NCT02520011
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Tolero Pharmaceuticals | Tolero Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Colorectal Neoplasms (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Melanoma (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 14